Log In Sign up
The largest database of trusted experimental protocols
> Procedures > Laboratory Procedure > Urine Specimen Collection

Urine Specimen Collection

Urine Specimen Collection is the process of obtaining a sample of urine for analysis and diagnostic purposes.
It involves various techniques to collect urine from individuals, ensuring the sample is representative and uncontaminated.
The collection methods may include clean-catch, midstream, or catheterization procedures, depending on the patient's condition and the specific testing requirements.
Accurate urine specimen collection is crucial for reliable laboratory analyses, disease screening, and monitoring of various health conditions.
Proper collection protocols help enhance reproducibility and accuracy, supporting effective clinical decision-making.

Most cited protocols related to «Urine Specimen Collection»

1
Comprehensive Multi-Site Physiological Assessment Protocol
After arriving at one of the three participating sites, respondents were escorted by project staff to the clinic where they were checked in, and were then escorted to the room where they would stay overnight. In most cases, respondents arrived mid-afternoon of Day 1 of their visit and ended their stay by noon of Day 2. On Day 1, with staff assistance, they completed the medical history, the bone densitometry scan, and physical exam, each of which required 30–45 minutes. They were also given the self-administered questionnaire (SAQ) to complete that evening (see www.midus.wisc.edu for copies of assessment instruments, which are included under descriptions of the MIDUS II projects) Clinic nursing staff began collecting the 12 hour urine specimen (collection period 7 p.m. to 7 a.m.). On Day 2 nursing staff collected the fasting blood specimen and completed the 12 hour urine specimen collection.
After breakfast, project staff carried out an experimental protocol assessing physiological response to, and recovery from, cognitive and orthostatic challenges similar to stressors people experience in their daily lives. The protocol consisted of a series of two randomized 6 minute cognitive challenges, one involving a math task and the other a Stroop-like test (decision-making about stimuli in which letters and colors are in conflict), followed by a 6 minute orthostatic (standing) challenge. Each challenge was followed by a 6 minute recovery period. Physiological reactivity throughout the experimental protocol was monitored via measures of blood pressure, heart rate variability and respiration, and salivary cortisol. Completed SAQs were then collected, and respondents were debriefed. At the UW-Madison data collection site, information was given about completing objective sleep assessments, to be returned by mail, after returning home. At the end of their visits, respondents were given a report about their blood pressure, body mass index (BMI), and waist-hip ratio. They were sent letters reporting cholesterol, HAlc, and bone density 1–2 months after the clinic visit.
To ensure consistency across sites and optimize the pace and quality of data collection, project staff and clinic nursing staff at all three sites followed standardized procedures that were detailed in a general Manual of Procedures, as well as more specific Guidelines for Collecting and Processing Biomarkers, and a Psychophysiology Manual. An administrative database was used to facilitate management and tracking of cross-project participation as well as tracking of participation at the three Project 4 sites. This information allowed review of participation information and quality control assessments, including identifying areas where additional staff training was required. Monthly conference calls with staff and investigators from all sites provided a forum to discuss issues or problems. Prior to these calls, each site generated a “Progress Report”, using report queries built into the administrative database; the reports were circulated for review by all on the conference call.
Love G.D., Seeman T.E., Weinstein M, & Ryff C.D. (2010). Bioindicators in the MIDUS National Study: Protocol, Measures, Sample, and Comparative Context. Journal of aging and health, 22(8), 1059-1080.
Publication 2010
Biological Markers BLOOD Blood Pressure Bone Density Bones Cholesterol Clinic Visits Cognition Conferences Densitometry Hydrocortisone Index, Body Mass Life Experiences Nursing Staff Physical Examination physiology Rate, Heart Respiration Sleep Urine Specimen Collection Waist-Hip Ratio
2
Assessing Depression and Cardiovascular Risk
The primary goal of the Heart and Soul Study was to determine why depression is associated with an increased risk of cardiovascular events in outpatients with stable coronary heart disease.25 (link) We used administrative databases to identify outpatients with documented coronary artery disease at 2 Department of Veterans Affairs Medical Centers (San Francisco VA Medical Center and the VA Palo Alto Health Care System, California), 1 university medical center (University of California, San Francisco), and 9 public health clinics in the Community Health Network of San Francisco.
Patients were eligible to participate if they had at least 1 of the following: a history of myocardial infarction, angiographic evidence of at least 50% stenosis in 1 or more coronary vessels, prior evidence of exercise-induced ischemia by treadmill or nuclear testing, a history of coronary revascularization, or a diagnosis of coronary artery disease documented by an internist or cardiologist. Between September 11, 2000, and December 20, 2002, a total of 1024 participants were enrolled: 240 from the public health clinics, 346 from the university medical center, and 438 from the VA medical centers.
All participants completed a baseline examination that included an interview, fasting blood draw, psychiatric interview, questionnaire, echocardiogram, exercise treadmill test, 24-hour ambulatory electrocardiogram, and 24-hour urine collection. Of the 1024 participants who completed the baseline examination, we were not able to contact 7 (<1%) during the follow-up period, leaving 1017 for this analysis. Our protocol was approved by the appropriate institutional review boards, and all participants provided written informed consent.
Whooley M.A., de Jonge P., Vittinghoff E., Otte C., Moos R., Carney R.M., Ali S., Dowray S., Na B., Feldman M.D., Schiller N.B, & Browner W.S. (2008). Depressive Symptoms, Health Behaviors, and Risk of Cardiovascular Events in Patients With Coronary Heart Disease. JAMA : the journal of the American Medical Association, 300(20), 2379-2388.
Publication 2008
Angiography BLOOD Cardiologists Coronary Arteriosclerosis Coronary Artery Disease Coronary Vessels Diagnosis Echocardiography Electrocardiography, Ambulatory Ethics Committees, Research Exercise Tests Heart Ischemia Myocardial Infarction Outpatients Patients Stenosis Urine Specimen Collection Veterans
3
Prenatal Toxicant Exposure and Preterm Birth
This study was conducted among pregnant women participating in the “Puerto Rico Testsite for Exploring Contamination Threats (PROTECT)” project, an ongoing prospective birth cohort in the Northern Karst Region of Puerto Rico, which is designed to evaluate the relationship between environmental toxicants and risk of preterm delivery. Study participants were recruited at approximately 14±2 weeks of gestation at seven prenatal clinics and hospitals throughout Northern Puerto Rico during 2010-2012. Women were eligible if they were between the ages of 18 to 40 years, resided in a municipality within the Northern karst region, didn’t use oral contraceptives three months prior to pregnancy or in vitro fertilization as a method of assisted reproductive technology, and were free of known medical/obstetrics complications. Women provided spot urine samples at three separate study visits (20±2 weeks, 24±2 weeks, and 28±2 weeks of gestation). Questionnaires to collect demographic information and data on self-reported product use in the 48 hours preceding urine sample collection were also administered at each visit.
The present analysis reflects the first105 women recruited into the study who had urinary biomarker data as of June 2012. The research protocol was approved by the Ethics and Research Committees of the University of Puerto Rico and participating clinics, the University of Michigan School of Public Health, and Northeastern University. The involvement of the Centers for Disease Control and Prevention (CDC) laboratory was determined not to constitute engagement in human subjects research. The study was described in detail to all participants, and informed consent was obtained prior to study enrollment.
Meeker J.D., Cantonwine D.E., Rivera-González L.O., Ferguson K.K., Mukherjee B., Calafat A.M., Ye X., Anzalota Del Toro L.V., Crespo N., Jiménez-Vélez B., Alshawabkeh A.N, & Cordero J.F. (2013). Distribution, variability and predictors of urinary concentrations of phenols and parabens among pregnant women in Puerto Rico. Environmental science & technology, 47(7), 3439-3447.
Publication 2013
Assisted Reproductive Technologies Biological Markers Birth Cohort Contraceptives, Oral Fertilization Fertilization in Vitro Homo sapiens In Vitro Techniques Pregnancy Pregnant Women Premature Birth Urine Urine Specimen Collection Woman
4
Cardiovascular Disease Evaluation in MACS
The Multicenter AIDS Cohort Study (MACS) is an ongoing prospective cohort study of the natural and treated histories of HIV-1 infection in homosexual and bisexual men, conducted in Baltimore, Chicago, Pittsburgh and Los Angeles (17 (link)). Initial enrollment in the MACS parent study occurred in 1984–85, with additional enrollment in 1987–1991 and 2001–2003. The cohort includes both HIV-infected and uninfected men who attend semiannual research visits including standardized interviews, physical examinations and blood and urine collection for laboratory measurements.
Eligibility for this MACS cardiovascular ancillary study included being an active MACS participant (with oversampling of HIV-infected men), age 40–70 years, weight< 300 lbs, and no prior history of cardiac surgery or percutaneous coronary intervention, as these procedures would interfere with the measurement of coronary atherosclerosis. All participants completed non-contrast cardiac CT scanning for coronary artery calcium (CAC) scoring between January 2010 and August 2013. Men with atrial fibrillation, chronic kidney disease [estimated glomerular filtration rate (GFR)<60 ml/min/m2 during a prior MACS study visit] or a history of IV contrast allergy were excluded from CTA studies. All eligible CTA participants had an estimated GFR>60 ml/min/m2 within one month of CTA. The study was approved by the Institutional Review Boards of all participating sites. All participants signed informed consent for this MACS ancillary study.
Post W.S., Budoff M., Kingsley L., Palella FJ J.r., Witt M.D., Li X., George R.T., Brown T, & Jacobson L.P. (2014). Associations between HIV Infection and Subclinical Coronary Atherosclerosis: The Multicenter AIDS Cohort Study (MACS). Annals of internal medicine, 160(7), 458-467.
Publication 2014
Acquired Immunodeficiency Syndrome Artery, Coronary Atrial Fibrillation Bisexuals BLOOD Calcium Cardiovascular System Chronic Kidney Diseases Coronary Arteriosclerosis Eligibility Determination Ethics Committees, Research First Aid Glomerular Filtration Rate Heart HIV-1 HIV Infections Homosexuals Hypersensitivity Infection Parent Percutaneous Coronary Intervention Physical Examination Surgical Procedure, Cardiac Urine Specimen Collection
5
Assessing Kidney Function and Cardiometabolic Risks
The methods of urine collection to assess ACR, PCR, and urine dipstick varied by eligible cohort, including collections of morning spot urine, random spot urine, and 24-hour urine (Appendix 1). Estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation.(30 (link)) In cohorts where the creatinine measurement was not standardized to isotope dilution mass spectrometry, values were multiplied by 0.95 before eGFR calculation.(31 (link)) We defined diabetes as fasting glucose ≥7.0 mmol/L (126 mg/dL), non-fasting glucose ≥11.1 mmol/L (200 mg/dL), hemoglobin A1c ≥6.5%, use of glucose lowering drugs, or self-reported diabetes. Hypertension was defined as blood pressure >140/90 mm Hg or the use of anti-hypertensive medications. Participants with a history of myocardial infarction, coronary revascularization, heart failure, or stroke were considered to have a history of cardiovascular disease.
Sumida K., Nadkarni G.N., Grams M.E., Sang Y., Ballew S.H., Coresh J., Matsushita K., Surapaneni A., Brunskill N., Chadban S.J., Chang A.R., Cirillo M., Daratha K.B., Gansevoort R.T., Garg A.X., Iacoviello L., Kayama T., Konta T., Kovesdy C.P., Lash J., Lee B.J., Major R., Metzger M., Miura K., Naimark D.M., Nelson R.G., Sawhney S., Stempniewicz N., Tang M., Townsend R.R., Traynor J.P., Valdivielso J.M., Wetzels J., Polkinghorne K.R, & Heerspink H.J. (2020). Conversion of urine protein-creatinine ratio or urine dipstick to urine albumin-creatinine ratio for use in CKD screening and prognosis: An individual participant-based meta-analysis. Annals of internal medicine, 173(6), 426-435.
Publication 2020
Antihypertensive Agents Blood Pressure Cardiovascular Diseases Cerebrovascular Accident Congestive Heart Failure Creatinine Diabetes Mellitus Glomerular Filtration Rate Glucose Heart Hemoglobin A, Glycosylated High Blood Pressures Isotopes Mass Spectrometry Myocardial Infarction Pharmaceutical Preparations Technique, Dilution Urine Urine Specimen Collection

Most recents protocols related to «Urine Specimen Collection»

1
In Vivo Evaluation of SYN-PKU-2002 Activity
Not available on PMC !

Example 66

The activity of SYN-PKU-2002 was assessed in vivo. To prepare the cells for the study, SYN-PKU901 and SYN-PKU-2002 overnight cultures were each used to inoculate 4 2 L flasks containing 500 mL of LB with DAP100 ug/mL. These cultures were grown for 1 hr and 45 min and then moved to the anaerobic chamber supplying 90% N2, 5% CO2, and 5% H2 for 4 hours. Cells were then spun down at 4600×G for 12 min and resuspended in 10 mL of formulation buffer (Glycerol: 15% (v/v), Sucrose: 10% (w/v) (100 g/L), MOPS: 10 mM (2.1 g/L), NaCl: 25 mM (1.46 g/L)). Several 40 ul aliquots were removed to be used for cell counting and activity determination. The viability as determined by cellometer count (in quadruplicate) 6.94e10 cfu/ml (+/−5.78e9).

Activity was determined using a plate based assay. Briefly, 1×108 cfu as determined by cellometer were added to 1 ml of prewarmed assay buffer (1× M9 minimal media containing 0.5% glucose, 50 mM MOPS, and 50 mM phenylalanine) in a microfuge tube, vortexed briefly, and immediately placed in a heat block or water bath at 37 degrees Celsius for static incubation (t=0). Supernatant samples from cells re-suspended in assay buffer were analyzed for the abundance of TCA over several time points using spectrophotometer at an absorbance of 290 nm. The accurate OD290 window for TCA detection occurs in a relatively narrow concentration range. For this reason, supernatant samples were diluted to ensure that the absorbance measurement fell into the linear range for detection. Measurements were compared to a TCA standard curve. Activity was determined to be 2.72 umol/hr/le9 cfu (+/−0.15 umol/hr/le9 cfu).

Beginning 4 days prior to the study (i.e., Days −4-1), Pah ENU2/2 mice (˜11-15 weeks of age) were maintained on phenylalanine-free chow and water that was supplemented with 0.5 grams/L phenylalanine. On the day of the study, mice were randomized into treatment groups according to weight as follows: Group 1: SYN-PKU901 (n=9); Group 2: Group 2: SYN-PKU-2002 (n=9). Blood samples were collected by sub-mandibular skin puncture to determine baseline phenylalanine levels. Mice were then administered single dose of phenylalanine by subcutaneous injection at 0.1 mg per gram body weight, according to the average group weight. At 1, 2 and 3 h post Phe challenge, the bacteria (or water) were administered to mice by oral gavage (3×250 ul). Whole blood was collected via submandibular bleed at each time point. Urine collection in metabolic caging commenced immediately after the 1st bacterial dose and continued to be collected for the duration of the study (4 hours).

Blood samples were kept on ice until processing for plasma in a centrifuge (2000 g for 10 min at 4 C) within 20 min of collection. Plasma was then transferred into a 96-well plate for MS analysis. Urine was collected in 5 mL tubes and volumes were recorded before transferring samples to MS for analysis. Results are shown in FIG. 17A and FIG. 17B and show that SYN-PKU-2002 causes decreased changes in phenylalanine post-Phe injection and produces hippurate, in a similar manner as SYN-PKU-710.

US11879123B2. Bacteria for the treatment of disorders (2024-01-23). Synlogic Operating Company, Inc. [US]. Inventors: Dean Falb [US], Adam B. Fisher [US], Vincent M. Isabella [US], Jonathan W. Kotula [US], David Lubkowicz [US], Paul F. Miller [US], Yves Millet [US], Sarah Elizabeth Rowe [US].
Patent 2024
Bacteria Bath Biological Assay BLOOD Buffers Cells Glucose Glycerin hippurate Mandible morpholinopropane sulfonic acid Mus Plasma Punctures Serum Skin Sodium Chloride Subcutaneous Injections Sucrose Tube Feeding Urine Urine Specimen Collection
2
Efficacy of Casein for Phe, TCA, and HA Consumption
Not available on PMC !

Example 77

Efficacy of replacing peptones (composed of small peptides) with casein (a whole protein) for expressing Phe, TCA, and HA consumption was evaluated.

At T=0, urine pans were emptied, and NHPs were administered an oral gavage of 28 mL of casein (4.5 g)/biocarbonate/D5-phenylalanine (25 mg; 8 mg/kg). NHPs 1-5 were further administered an oral gavage of 3.5 mL SYN-PKU-2002 (5×1011 CFU), and NHPs 6-10 were administered 3.5 mL formulation buffer via oral gavage. Concurrently, the NHPs were administered a flush with 2 mL of water. Animals were bled at 0, 0.5, 1, 2, 4, and 6 h by venipuncture. At 6 h post dosing, the urine collection pan was removed and the contents poured into a graduated cylinder for volume measurement of 5 mL. Results are shown in FIGS. 118A-118C.

The results from this study demonstrate that the genetically engineered bacterial strains of the disclosure can consume Phe that is naturally digested and can prevent a spike in blood Phe observed in the control upon D5-Phe consumption.

US11879123B2. Bacteria for the treatment of disorders (2024-01-23). Synlogic Operating Company, Inc. [US]. Inventors: Dean Falb [US], Adam B. Fisher [US], Vincent M. Isabella [US], Jonathan W. Kotula [US], David Lubkowicz [US], Paul F. Miller [US], Yves Millet [US], Sarah Elizabeth Rowe [US].
Patent 2024
Animals Bacteria BLOOD Buffers Caseins Figs Flushing Homo sapiens Peptides Peptones Primates Proteins Strains Tube Feeding Urine Urine Specimen Collection Venipuncture
3
Assessing LAAD Expression Effect on Phe Metabolism
Not available on PMC !

Example 74

Efficacy of of LAAD expression and determination of any negative effects on PAL metabolism of Phe was assessed.

At T=0, the urine pan was emptied, and Non-Human Primates (NHPs) were orally administered 5.5 g of Peptone from meat in 11 mL, and 10 mL of an oral gavage bacteria. A SYN-PKU-2001 (5×1011 CFU) oral gavage bacteria strain was administered to NHP's 1-3. A SYN-PKU-2001 (5×1011 CFU) without LAAD was administered to NHP's 4-6. Both strains were suspended in formulation buffer (previously grown in activated in a bioreactor and thawed on ice) or formulation buffer alone as a mock. Concurrently, NHP's 1-10 were all administered 5 mL of 0.36M sodium bicarbonate followed by a flush with 5 mL of water Animals were bled at 0, 0.5, 1, 2, 4, and 6 h by venipuncture. At 6 h post dosing, the urine collection pan was removed and the contents poured into a graduated cylinder for volume measurement of 5 mL. Results are shown in FIG. 24A and FIG. 24B confirm that expression of LAAD did not have a negative effect on PAL metabolism of Phe.

US11879123B2. Bacteria for the treatment of disorders (2024-01-23). Synlogic Operating Company, Inc. [US]. Inventors: Dean Falb [US], Adam B. Fisher [US], Vincent M. Isabella [US], Jonathan W. Kotula [US], David Lubkowicz [US], Paul F. Miller [US], Yves Millet [US], Sarah Elizabeth Rowe [US].
Patent 2024
Animals Bacteria Bicarbonate, Sodium Bioreactors Buffers Flushing Homo sapiens Meat Metabolism Peptones Primates Strains Tube Feeding Urine Urine Specimen Collection Venipuncture
4
Comprehensive T2DM Metabolic Profiling
A trained interviewer recorded patients’ information, including demographic characteristics, duration of T2DM, and medical history. The height and weight of patients without shoes and with light clothes to the nearest 100 g were measured using the same device (Seca weighing scale, made in Germany), and body mass index (BMI) was calculated by dividing weight (kg) into height squared (meters).
After 8 to 12 h of overnight fasting, a blood sample was taken from all participants to measure cell counts, iron profiles (total iron-binding capacity (TIBC), hemoglobin concentration, serum ferritin, and iron level), triglyceride, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), fasting plasma glucose (FPG), and glycated hemoglobin (Hb A1c). Also, urine sample was taken from the participants. All of them were measured in a same lab with same kits, devices, and methods.
FPG was measured by the colorimetric glucose oxidase method (Human, Heidelberg Germany). Furthermore, TC, HDL-C, and triglyceride were measured by enzymatic method using a proper kit (Lipid, Pars Azmoon Co., Karaj, Iran). Also, if triglyceride levels were < 400 mg/dL, the Friedewald formula (LDL = total cholesterol - (HDL + TG/5)) was applied for calculating LDL-C, and if triglycerides were ≥ 400 mg/dL, LDL-C was measured by direct assay. Hb A1C was assessed by column chromatography. TIBC was measured by the chemical precipitation method. Also, ferritin was measured by the immunoassay method using a gamma counter. Urinary albumin excretion was assessed by the immunoturbidometry method of a 24 hour’s urine collection. Serum creatinine levels were measured using kinetic colorimetric Jaffe with a sensitivity of 0.2 mg/dL (range, 0.2–15 mg/dL). The Modification of Diet in Renal Disease (MDRD) equation was employed for calculating the estimated glomerular filtration rate (e-GFR) of the participants [15 , 16 (link)].
Hizomi Arani R., Fakhri F., Naeimi Tabiee M., Talebi F., Talebi Z., Rashidi N, & Zahedi M. (2023). Prevalence of anemia and its associated factors among patients with type 2 diabetes mellitus in a referral diabetic clinic in the north of Iran. BMC Endocrine Disorders, 23, 58.
Publication 2023
Albumins Biological Assay BLOOD Chemical Precipitation Cholesterol Cholesterol, beta-Lipoprotein Chromatography Colorimetry Creatinine Enzymes Ferritin Gamma Rays Glomerular Filtration Rate Glucose Hemoglobin Hemoglobin, Glycosylated Hemoglobin A, Glycosylated High Density Lipoprotein Cholesterol Homo sapiens Hypersensitivity Immunoassay Index, Body Mass Interviewers Iron Kidney Diseases Kinetics Light Lipids Medical Devices Oxidase, Glucose Patients Plasma Poly(ADP-ribose) Polymerases Serum Therapy, Diet Triglycerides Urine Urine Specimen Collection
5
Anemia, Diabetes, and Cardiometabolic Profiles
Anemia was considered as hemoglobin less than 12 g/dL in women and less than 13 g/dL in men according to the World Health Organization (WHO) criteria (12). DM was defined as FPG ≥ 126 mg/dL and/or Hb A1c ≥ 6.5 or taking any GLDs. The participants were categorized into two groups: BMI < 30 kg/m2 (normal/overweight) and ≥ 30 kg/m2 (obese). Chronic kidney disease (CKD) was considered as e-GFR lower than 60 mL/ min/1.73m2 according to the kidney disease outcomes quality initiative (KDQOI) guidelines [17 (link)]. Albuminuria was considered as urinary albumin creatinine ratio (ACR) of 30 mg or more in 24 hours’ urine collection. Hypertriglyceridemia was defined as TG more than 150 mg/dL and hypercholesterolemia was considered TC more than 200 mg/dL.
Hizomi Arani R., Fakhri F., Naeimi Tabiee M., Talebi F., Talebi Z., Rashidi N, & Zahedi M. (2023). Prevalence of anemia and its associated factors among patients with type 2 diabetes mellitus in a referral diabetic clinic in the north of Iran. BMC Endocrine Disorders, 23, 58.
Publication 2023
Albumins Anemia Cell Leukodystrophy, Globoid Chronic Kidney Diseases Creatinine Hemoglobin Hemoglobin A, Glycosylated Hypercholesterolemia Hypertriglyceridemia Kidney Diseases Obesity Urine Urine Specimen Collection Woman

Top products related to «Urine Specimen Collection»

1
Bp 98a by Softron
Sourced in Japan, China
The BP-98A is a laboratory instrument designed for measuring blood pressure. It provides accurate readings of systolic and diastolic blood pressure values.
2
Albuwell m by Exocell
Sourced in United States
The Albuwell M is a laboratory equipment designed for the detection and measurement of albumin levels in urine samples. It provides a standardized and reliable method for quantifying albumin concentrations.
3
Cobas 6000 by Roche
Sourced in Switzerland, Germany, United States, Japan, Denmark, Italy, France, United Kingdom, Belgium, Norway, China, Israel, Poland, Netherlands, Sweden
The Cobas 6000 is an automated clinical chemistry and immunoassay analyzer system designed for high-volume laboratory testing. It combines the features of two separate instruments, the Cobas c 501 module for clinical chemistry and the Cobas e 601 module for immunoassays, into a single integrated platform. The Cobas 6000 system is capable of performing a wide range of diagnostic tests, including biochemical, immunological, and specialty assays.
4
Metabolic cage by Tecniplast
Sourced in Italy, Germany, United States, France, Australia
Metabolic cages are laboratory equipment designed to monitor and collect data on an animal's metabolic processes, such as food and water intake, urine, and fecal output. These cages provide a controlled environment to facilitate the study of an animal's energy balance, nutrient utilization, and other physiological parameters.
5
Creatinine colorimetric assay kit by Cayman Chemical
Sourced in United States
The Creatinine Colorimetric Assay Kit is a laboratory product designed to measure the concentration of creatinine in biological samples. The kit utilizes a colorimetric reaction to quantify creatinine levels.
6
Cobas 8000 by Roche
Sourced in Switzerland, Germany, United States, Japan, France, Italy, China, United Kingdom, Sweden
The Cobas 8000 is a modular, automated in-vitro diagnostic system designed for high-throughput clinical chemistry and immunochemistry testing. It is used to perform a wide range of laboratory tests, including those for chemistry, immunoassay, and electrolyte analysis. The Cobas 8000 is capable of processing a large volume of samples efficiently and accurately.
7
Creatinine companion kit by Exocell
Sourced in United States
The Creatinine Companion kit is a lab equipment product designed for the measurement of creatinine levels in biological samples. The kit provides the necessary reagents and components to perform creatinine testing in a laboratory setting.
8
Bradford assay by Bio-Rad
Sourced in United States, Germany, United Kingdom, Italy, Canada, China, France, Switzerland, Austria, Spain, Japan, Australia, Brazil, Ireland, Sweden
The Bradford assay is a colorimetric protein assay used to measure the concentration of protein in a solution. It is based on the color change of the Coomassie Brilliant Blue G-250 dye in response to various concentrations of protein.

More about "Urine Specimen Collection"

Urine Collection: A Critical Step for Reliable Analysis and Diagnosis.
Gather urine samples accurately and efficiently with various techniques like clean-catch, midstream, or catheterization.
Ensure sample integrity and minimize contamination for trustworthy lab results.
Discover the latest protocols from literature, preprints, and patents using AI-powered tools like PubCompare.ai.
Enhance reproducibility and accuracy with intelligent comparisons of collection methods and products.
Explore related terms like BP-98A, Albuwell M, Cobas 6000, Metabolic cages, Creatinine Colorimetric Assay Kit, Cobas 8000, and Creatinine Companion kit to optimize your urine specimen collection and unlock insights for effective clinical decision-making.
Don't let a typo ruin your research - trust the experts to guide you through the process.